Gram-Negative
Haemophilus influenzae Infection Models
In vivo efficacy testing against Haemophilus influenzae, a WHO medium-priority respiratory pathogen, in a pulmonary model with quantitative burden and survival endpoints.
Haemophilus influenzae (H. influenzae) is a fastidious Gram-negative coccobacillus that colonizes the upper respiratory tract and, when it spreads beyond it, causes disease ranging from ear and sinus infections to pneumonia and the invasive syndromes of bacteremia and meningitis. Despite its name – assigned when it was mistakenly thought to cause influenza – it is a bacterium, and its epidemiology has been reshaped by vaccination.
Encapsulated type b (Hib) was once the leading cause of bacterial meningitis in young children; the Hib conjugate vaccine has made invasive type b disease rare in vaccinated populations, and as a result non-typeable H. influenzae (NTHi) – the unencapsulated form, against which the vaccine does not protect – is now the predominant cause of H. influenzae infection. NTHi drives acute otitis media, sinusitis, and exacerbations of chronic obstructive pulmonary disease, causes community-acquired pneumonia, and produces invasive disease in children, older adults, and people with underlying conditions.
The WHO lists ampicillin-resistant H. influenzae in the medium-priority tier of its 2024 Bacterial Priority Pathogens List. TransPharm Preclinical Solutions evaluates candidates against H. influenzae in a pulmonary infection model and produces the quantitative burden and survival data a development program needs.
Scientific Scope
The scientific problem in an H. influenzae study is matching the challenge to the modern epidemiology of the organism. Because NTHi now accounts for most disease, a non-typeable respiratory isolate is the clinically representative challenge for the indications where new agents are most needed. Resistance status is the second variable: ampicillin resistance in H. influenzae arises by two distinct routes – β-lactamase production and altered penicillin-binding proteins – that respond differently to β-lactam and β-lactamase-inhibitor combinations, so the resistance phenotype of the challenge strain determines what a study can show. The organism is also fastidious, requiring specific growth factors, which is a practical consideration in study design and susceptibility testing.
TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized H. influenzae isolates, including defined resistant phenotypes, to a program’s specifications.
Validated Infection Models
Every study parameter is configurable to the scientific question: challenge strain, host species and strain, route of administration, comparator agents, and dosing schedule. The core readouts are quantitative bacterial burden (CFU) in target tissues, organs, and blood, with survival and mortality tracking where applicable.
The following are available as add-ons to any study:
- Pharmacokinetic profiling and PK/PD analysis
- Blood chemistry
- Additional tissue harvests
- Histopathology
Pulmonary Infection
The lung is the setting in which H. influenzae – and NTHi in particular – causes much of its burden, from community-acquired pneumonia to the exacerbations that drive morbidity in chronic lung disease. The pulmonary model is the appropriate choice when the development question is reduction of pulmonary burden, survival after airway challenge, or delivery of an inhaled or systemically dosed agent to infected lungs. Animals are challenged by intranasal or intratracheal instillation. Test article may be delivered by nebulization, oral gavage, intranasal or intratracheal instillation, or by intravenous, intraperitoneal, intramuscular, or subcutaneous injection. Endpoints include survival and CFU burden in lung and other harvested tissues. Validated in mice. Validated H. influenzae isolate: 54A1218, a non-typeable strain.
In Vitro Susceptibility Testing
In vitro susceptibility testing complements the in vivo model. H. influenzae MIC is determined by broth microdilution per CLSI, using the specialized medium the organism requires, and β-lactamase testing and the detection of PBP3-mediated resistance situate a candidate against the two mechanisms that define this pathogen’s resistance. Time-kill and checkerboard analysis can be added to characterize a candidate and its combinations.
Antimicrobial Resistance
Ampicillin and other aminopenicillins are the historical first-line therapy for H. influenzae, and resistance to them proceeds by two mechanisms that matter differently to drug developers. The first and long-dominant route is β-lactamase production – most often the TEM-1 enzyme, less commonly ROB-1 – which hydrolyzes ampicillin but is neutralized by a β-lactamase inhibitor such as clavulanate; these isolates are termed β-lactamase-positive, ampicillin-resistant. The second, increasingly important route is β-lactamase-negative ampicillin resistance (BLNAR), caused by mutations in the ftsI gene that alter penicillin-binding protein 3 and lower its affinity for β-lactams. BLNAR strains are not rescued by β-lactamase inhibitors, can extend to reduced susceptibility to cephalosporins, and are harder to detect reliably in the clinical laboratory; strains carrying both mechanisms compound the problem. Because these routes respond differently to the drugs and combinations a program may be developing, the resistance mechanism of the challenge strain determines what an efficacy study can claim.